GI Innovation secures European formulation patent for immuno-oncology candidate '안전한 바카라 사이트101A'

[by Kang, In Hyo] GI Innovation announced on September 9 that a formulation patent for its immuno-oncology drug candidate, ‘GI-101A (development code),’ has been granted in Europe.

The patent covers formulation technology designed to improve 안전한 바카라 사이트101A's stability, delivery efficiency, and patient convenience. According to the company, the patent holds significant clinical and commercial value, as it is applicable to both intravenous (IV) and subcutaneous (SC) formulations.

GI Innovation has developed its proprietary platform capable of screening optimal formulations tailored to the characteristics of its pipeline, and the newly granted patent was secured on the basis of this technological capability. The patent provides a longer protection term than the existing 안전한 바카라 사이트101A compound patent, thereby strengthening the company’s intellectual property portfolio for 안전한 바카라 사이트101A and representing a significant milestone in its global commercialization strategy.

안전한 바카라 사이트101A is currently being prepared for entry into Phase 2 clinical trials. In these studies, the company intends to focus on high-market potential indications, including non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and cervical cancer, where Keytruda combination therapy demonstrated strong anticancer activity in Phase 1b trials.

Moreover, with the recent report of a complete remission (CR) in a Phase 1 subcutaneous monotherapy trial of 안전한 바카라 사이트102 at the Mayo Clinic in the United States, attention is also turning to the potential expansion of 안전한 바카라 사이트101A into a subcutaneous formulation. GI Innovation has previously secured material, immune checkpoint inhibitor combination, and anticancer combination patents for 안전한 바카라 사이트101A in key markets, including the United States. Following Japan and China, the company has now obtained a formulation patent in Europe.

“Our formulation screening platform represents a key differentiating capability for the company,” said Jang Myoung-ho, CEO of GI Innovation. “With foreign ownership gradually increasing following our recent inclusion in the MSCI index, we anticipate that securing this European formulation patent will further increase the interest among European investors,” he added.